Global Blood Therapeutics
Data Breaches and Security Report

https://gbt.com  ᛫  Biotech & Pharmaceuticals
Last updated August 24, 2019

Company Details

Company Overview

GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing its late-stage product candidate, voxelotor (previously called GBT440), for the treatment of sickle cell disease.

Valuation

Employees

CEO

Ted W. Love, M.D.

Location

Data Breaches and Security News

Security Rating

Sorry, this security report couldn't be loaded at this time. Please try again later.

UpGuard's Cyber Security Ratings range from 0 to 950. The higher the score, the more effective a company is in implementing good security practices.

Passed Checks

Passed{{ passedCheck.passTitle }}

Failed Checks

Warning{{ failedCheck.failTitle }}

View a free security report for Global Blood Therapeutics

Get full security report ›

Related posts

Learn more about the latest issues in cybersecurity

More security reports

Compare Global Blood Therapeutics's security performance with other companies